Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UA026 in healthy volunteers and moderate to severe plaque psoriasis
NCT07038720Phase 1Recruiting
- Sponsor
- Usynova Pharmaceuticals
- Start
- May 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing UA026 with Placebo (2 arms). Primary endpoints: Adverse Events at 56 days, Vital Signs at 56 days and 3 more. Started May 2025; status: recruiting.
02
Drugs
UA026
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07038720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038720.